Copyright Reports & Markets. All rights reserved.

Global Myasthenia Gravis (MG) Treatment Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Myasthenia Gravis (MG) Treatment Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Drug Treatment
      • 1.4.3 Rapid Immunotherapies
      • 1.4.4 Others
    • 1.5 Market by Application
      • 1.5.1 Global Myasthenia Gravis (MG) Treatment Market Share by Application (2019-2025)
      • 1.5.2 Hospitals and Clinics
      • 1.5.3 Diagnostic Centers
      • 1.5.4 Academic and Research Organizations
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Myasthenia Gravis (MG) Treatment Market Size
    • 2.2 Myasthenia Gravis (MG) Treatment Growth Trends by Regions
      • 2.2.1 Myasthenia Gravis (MG) Treatment Market Size by Regions (2019-2025)
      • 2.2.2 Myasthenia Gravis (MG) Treatment Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Myasthenia Gravis (MG) Treatment Market Size by by Players
      • 3.1.1 Global Myasthenia Gravis (MG) Treatment Revenue by by Players (2014-2019)
      • 3.1.2 Global Myasthenia Gravis (MG) Treatment Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Myasthenia Gravis (MG) Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2 Myasthenia Gravis (MG) Treatment Key Players Head office and Area Served
    • 3.3 Key Players Myasthenia Gravis (MG) Treatment Product/Solution/Service
    • 3.4 Date of Enter into Myasthenia Gravis (MG) Treatment Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Myasthenia Gravis (MG) Treatment Market Size by Type (2014-2019)
    • 4.2 Global Myasthenia Gravis (MG) Treatment Market Size by Application (2014-2019)

    5 North America

    • 5.1 North America Myasthenia Gravis (MG) Treatment Market Size (2014-2019)
    • 5.2 Myasthenia Gravis (MG) Treatment Key Players in North America
    • 5.3 North America Myasthenia Gravis (MG) Treatment Market Size by Type
    • 5.4 North America Myasthenia Gravis (MG) Treatment Market Size by Application

    6 Europe

    • 6.1 Europe Myasthenia Gravis (MG) Treatment Market Size (2014-2019)
    • 6.2 Myasthenia Gravis (MG) Treatment Key Players in Europe
    • 6.3 Europe Myasthenia Gravis (MG) Treatment Market Size by Type
    • 6.4 Europe Myasthenia Gravis (MG) Treatment Market Size by Application

    7 China

    • 7.1 China Myasthenia Gravis (MG) Treatment Market Size (2014-2019)
    • 7.2 Myasthenia Gravis (MG) Treatment Key Players in China
    • 7.3 China Myasthenia Gravis (MG) Treatment Market Size by Type
    • 7.4 China Myasthenia Gravis (MG) Treatment Market Size by Application

    8 Japan

    • 8.1 Japan Myasthenia Gravis (MG) Treatment Market Size (2014-2019)
    • 8.2 Myasthenia Gravis (MG) Treatment Key Players in Japan
    • 8.3 Japan Myasthenia Gravis (MG) Treatment Market Size by Type
    • 8.4 Japan Myasthenia Gravis (MG) Treatment Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Myasthenia Gravis (MG) Treatment Market Size (2014-2019)
    • 9.2 Myasthenia Gravis (MG) Treatment Key Players in Southeast Asia
    • 9.3 Southeast Asia Myasthenia Gravis (MG) Treatment Market Size by Type
    • 9.4 Southeast Asia Myasthenia Gravis (MG) Treatment Market Size by Application

    10 India

    • 10.1 India Myasthenia Gravis (MG) Treatment Market Size (2014-2019)
    • 10.2 Myasthenia Gravis (MG) Treatment Key Players in India
    • 10.3 India Myasthenia Gravis (MG) Treatment Market Size by Type
    • 10.4 India Myasthenia Gravis (MG) Treatment Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Myasthenia Gravis (MG) Treatment Market Size (2014-2019)
    • 11.2 Myasthenia Gravis (MG) Treatment Key Players in Central & South America
    • 11.3 Central & South America Myasthenia Gravis (MG) Treatment Market Size by Type
    • 11.4 Central & South America Myasthenia Gravis (MG) Treatment Market Size by Application

    12 International Players Profiles

    • 12.1 Alexion Pharmaceutical
      • 12.1.1 Alexion Pharmaceutical Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Myasthenia Gravis (MG) Treatment Introduction
      • 12.1.4 Alexion Pharmaceutical Revenue in Myasthenia Gravis (MG) Treatment Business (2014-2019))
      • 12.1.5 Alexion Pharmaceutical Recent Development
    • 12.2 Grifols
      • 12.2.1 Grifols Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Myasthenia Gravis (MG) Treatment Introduction
      • 12.2.4 Grifols Revenue in Myasthenia Gravis (MG) Treatment Business (2014-2019)
      • 12.2.5 Grifols Recent Development
    • 12.3 Avadel Pharmaceuticals
      • 12.3.1 Avadel Pharmaceuticals Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Myasthenia Gravis (MG) Treatment Introduction
      • 12.3.4 Avadel Pharmaceuticals Revenue in Myasthenia Gravis (MG) Treatment Business (2014-2019)
      • 12.3.5 Avadel Pharmaceuticals Recent Development
    • 12.4 Novartis
      • 12.4.1 Novartis Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Myasthenia Gravis (MG) Treatment Introduction
      • 12.4.4 Novartis Revenue in Myasthenia Gravis (MG) Treatment Business (2014-2019)
      • 12.4.5 Novartis Recent Development
    • 12.5 Pfizer
      • 12.5.1 Pfizer Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Myasthenia Gravis (MG) Treatment Introduction
      • 12.5.4 Pfizer Revenue in Myasthenia Gravis (MG) Treatment Business (2014-2019)
      • 12.5.5 Pfizer Recent Development
    • 12.6 AbbVie
      • 12.6.1 AbbVie Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Myasthenia Gravis (MG) Treatment Introduction
      • 12.6.4 AbbVie Revenue in Myasthenia Gravis (MG) Treatment Business (2014-2019)
      • 12.6.5 AbbVie Recent Development
    • 12.7 F. Hoffmann-La Roche
      • 12.7.1 F. Hoffmann-La Roche Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Myasthenia Gravis (MG) Treatment Introduction
      • 12.7.4 F. Hoffmann-La Roche Revenue in Myasthenia Gravis (MG) Treatment Business (2014-2019)
      • 12.7.5 F. Hoffmann-La Roche Recent Development
    • 12.8 GlaxoSmithKline
      • 12.8.1 GlaxoSmithKline Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Myasthenia Gravis (MG) Treatment Introduction
      • 12.8.4 GlaxoSmithKline Revenue in Myasthenia Gravis (MG) Treatment Business (2014-2019)
      • 12.8.5 GlaxoSmithKline Recent Development
    • 12.9 Bausch Health Companies
      • 12.9.1 Bausch Health Companies Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Myasthenia Gravis (MG) Treatment Introduction
      • 12.9.4 Bausch Health Companies Revenue in Myasthenia Gravis (MG) Treatment Business (2014-2019)
      • 12.9.5 Bausch Health Companies Recent Development
    • 12.10 Shire
      • 12.10.1 Shire Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Myasthenia Gravis (MG) Treatment Introduction
      • 12.10.4 Shire Revenue in Myasthenia Gravis (MG) Treatment Business (2014-2019)
      • 12.10.5 Shire Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Product (2019-2025)
    • 13.2 Market Size Forecast by Application (2019-2025)
    • 13.3 Market Size Forecast by Regions
    • 13.4 North America
    • 13.5 Europe
    • 13.6 China
    • 13.7 Japan
    • 13.8 Southeast Asia
    • 13.9 India
    • 13.10 Central & South America

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 15.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      This report focuses on the global Myasthenia Gravis (MG) Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Myasthenia Gravis (MG) Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

      The key players covered in this study
      Alexion Pharmaceutical
      Grifols
      Avadel Pharmaceuticals
      Novartis
      Pfizer
      AbbVie
      F. Hoffmann-La Roche
      GlaxoSmithKline
      Bausch Health Companies
      Shire

      Market segment by Type, the product can be split into
      Drug Treatment
      Rapid Immunotherapies
      Others

      Market segment by Application, split into
      Hospitals and Clinics
      Diagnostic Centers
      Academic and Research Organizations

      Market segment by Regions/Countries, this report covers
      North America
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Myasthenia Gravis (MG) Treatment status, future forecast, growth opportunity, key market and key players.
      To present the Myasthenia Gravis (MG) Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Myasthenia Gravis (MG) Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
      Buy now